AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

-- AstraZeneca is in talks with Summit Therapeutics for a deal in which it could pay as much as $15 billion over time to license a lung-cancer drug, Bloomberg reported Thursday, citing people familiar ...

AstraZeneca PLC closed 23.78% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...